|
THE JENEX CORPORATION ISSUES PROGRESS REPORT FOR COLD SORE PREVENTION PRODUCT
September 26, 2005
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), is scheduled to begin manufacturing interceptCS™ , the first product proven and approved to prevent cold sores, and ship their initial order for international distribution by November 1st, 2005.
The Canadian retail launch is now scheduled for early first quarter, 2006. Michael Jenkins, President and CEO says, “We are delighted to have reached the commercialization stage for interceptCS . This is a significant milestone for Jenex. Our shareholders have been very patient during the development stage. We believe 2006 will be a successful and rewarding year for the company and our shareholders.”
Michael Mayo, Director of Marketing and Sales states, “Our strategic sales & marketing plans have been completed. The final details of our consumer and professional awareness campaign are now being reviewed for our Canadian launch. It is estimated, there are between 5 and 10 million recurrent cold sore sufferers in Canada. interceptCS has the potential to be a leader in this large and underdeveloped category.”
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. Patents in the United States, Canada, Australia and Europe protect the technology. The first device developed from this technology is the Therapik® product, for relief of pain and itch caused by insect stings and bites. Therapik® has been approved as a Class II medical device in Canada and the United States. In 2004, Jenex signed an exclusive multi-year licensing agreement for Therapik® for 22 Asian countries. Licensing partners are being pursued for other world markets. The second device, interceptCS is the first product proven and approved to prevent cold sores. Jenex has been approved to market interceptCS in Canada with its approved claim “For prevention and relief of the symptoms of herpes labialis (cold sores) such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. More information about the Corporation can be found at www.jenexcorp.com
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
|
